Renvela · DIN 02354586 · 800 mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot an ODB benefit; this DIN is on the ministry's EAP drug list (August 2026): submit an Exceptional Access request through SADIE with the clinical rationale; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Coverage criteria
Exceptional Access criteria on record are for Brand(s): Accel-Sevelamer; DOSAGE FORM/ STRENGTH: 800 mg tablet — not this product; no criteria on record for this product in this block.
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Lanthanum
Brand(s): Fosrenol and Generics
DOSAGE FORM/ STRENGTH: 250 mg, 500 mg, 750 mg, 1000 mg Chewable tablet
Sevelamer Hydrochloride
Brand(s): Renagel
DOSAGE FORM/ STRENGTH: 800 mg tablet
Sevelamer Carbonate
Brand(s): Accel-Sevelamer
DOSAGE FORM/ STRENGTH: 800 mg tablet
Sevelamer Carbonate
Brand(s): Renvela
DOSAGE FORM/ STRENGTH: 800 mg tablet, 0.8 g powder sachet, 2.4 g powder
sachet
Updated: June 7, 2021
i) For the treatment of hyperphosphatemia associated with end-stage renal disease
(ESRD) where patients are on dialysis and have a sustained serum phosphate > 1.8
mmol/L AND adjusted serum calcium > 2.65 mmol/L; OR
ii) For dialysis patients experiencing hyperphosphatemia (sustained serum phosphate
levels >1.8 mmol/L) who have calciphylaxis and/or evidence of coronary artery
calcification.
466
Notes:
1. Calcium and phosphate levels provided to demonstrate sustained elevations should be
at least 4 weeks apart.
2. Patients who demonstrate reduction of phosphate levels while on a calcium binder but
who experience adjusted serum calcium > 2.65 mmol/L must provide supporting
laboratory levels before treatment and while on treatment and should include the
dose(s) of calcium-based binder used.
Exclusion Criteria:
Sevelamer will not be reimbursed in the following cases:
Use in combination therapy with another funded non-calcium-based phosphate binder
(e.g. lanthanum carbonate hydrate, sucroferric oxyhydroxide, other sevelamer
formulations)
Duration of approval: lifetime
On a case-by-case basis, requests may be considered for sevelamer under the EAP for a
patient with serum phosphate less than 1.8mmol/L and calcium values less than 2.65
mmol/L.
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 466, record 305, corpus 2025-01-01; name match only, not an eligibility decision
1 brand, same coverage
Renvela · DIN 02354586
Manufacturer: Sanofi Aventis Pharma; listing date 2019-01-31
Health Canada: Marketed since 2014-07-24 · brand RENVELA · ATC V03AE02 SEVELAMER · form Tablet · route Oral · ingredients SEVELAMER CARBONATE 800 MG · company Sanofi-aventis canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordMinistry pays: $1.2634 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02354586)
Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02354586).
DIN 02354586: Renvela
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 401800009; group id 552; item number 1488; lccId None; manufacturer id SAV
Source form: Tab; strength: 800mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): $1.3125; ministry $1.2634
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02354586
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83974
Interchangeable products
Accel-Sevelamer · DIN 02461501 · $1.2634
Shortage status: Reversed (report reversed by the reporter); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02354586
Shortage record checked October 6, 2026